Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.33 |
| ▸ | DCUN1D2 | Q6PH85 | 1/20 | 0.33 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773521 | 0.86 | FYN (0.39) | DCUN1D1DCUN1D2AGTR1AGTR2FYN | |
| SCHEMBL3376281 | 0.84 | TRPA1 (0.35) | DCUN1D1DCUN1D2GP6AGTR1AGTR2 | |
| SCHEMBL1132111 | 0.84 | TAAR1 (0.43) | — | |
| SCHEMBL6962635 | 0.84 | AKT1 (0.36) | DCUN1D1DCUN1D2GP6AGTR1AGTR2 | |
| SCHEMBL6955822 | 0.84 | TP53 (0.41) | AGTR1AGTR2 | |
| SCHEMBL29366164 | 0.84 | TRPA1 (0.35) | DCUN1D1DCUN1D2GP6AGTR1AGTR2 | |
| SCHEMBL6956494 | 0.83 | TDP1 (0.40) | DCUN1D1DCUN1D2GP6 | |
| Hydrochloric Acid SCHEMBL1131050 | 0.83 | AKT2 (0.42) | — | |
| SCHEMBL6961100 | 0.82 | NPC1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL6962359 | 0.82 | MAOB (0.50) | GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | CHICAGO DISCOVERY SOLUTIONS, LLC | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | RUVBL2, RUVBL1, CYP2W1 | DCUN1D1 730/4885DCUN1D2 521/4885GP6 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.